0 0 0 0 -0.00599132291164523 -0.00144618139246614 -0.00568142689897402 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

3 Cash-Flow Machines Investors May Want Heading Into 2026 [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead is pushing long-acting HIV treatments based on lenacapavir—testing two paths (lenacapavir plus bNAbs infusions and lenacapavir plus the long-acting integrase GS-3242)—with pharmacokinetics supporting current four-month dosing and an objective of once-every-six-months regimens. For HIV prevention, the company is developing a 12-month lenacapavir PrEP using a higher-dose intramuscular formulation and an FDA-agreed model-based PK study, targeting a 2027 data readout and potential 2028 availability. Outside HIV, Gilead aims to expand liver-disease use of Livdelzi (the IDEAL phase III could roughly double the PBC addressable population ) while accelerating oncology via the Arcellx acquisition for anito-cel, broad Trodelvy pivotal programs, and long-term bets on in-vivo CAR-T. Interested in Gilead Sciences, Inc.? Here are five stocks we like better. 3 Blue-Chip Stocks Built for a Rotating Market Gilead Sciences (NASDAQ:GILD) executives outlined the company's approach to ne [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

3 Cash-Flow Machines Investors May Want Heading Into 2026 [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead is pushing long-acting HIV treatments based on lenacapavir—testing two paths (lenacapavir plus bNAbs infusions and lenacapavir plus the long-acting integrase GS-3242)—with pharmacokinetics supporting current four-month dosing and an objective of once-every-six-months regimens. For HIV prevention, the company is developing a 12-month lenacapavir PrEP using a higher-dose intramuscular formulation and an FDA-agreed model-based PK study, targeting a 2027 data readout and potential 2028 availability. Outside HIV, Gilead aims to expand liver-disease use of Livdelzi (the IDEAL phase III could roughly double the PBC addressable population ) while accelerating oncology via the Arcellx acquisition for anito-cel, broad Trodelvy pivotal programs, and long-term bets on in-vivo CAR-T. Interested in Gilead Sciences, Inc.? Here are five stocks we like better. 3 Blue-Chip Stocks Built for a Rotating Market Gilead Sciences (NASDAQ:GILD) executives outlined the company's approach to ne [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS